

## RESEARCH PAPER

# Total fertilization success and embryo formation in ART treatments; does it have any predictive value?

Marjan Omidi <sup>1</sup>, Azita Faramarzi <sup>2</sup>, Azam Agha-Rahimi <sup>1</sup>, Forough Sadat Farshchi <sup>1</sup>, Mohammad Ali Khalili <sup>1\*</sup>

<sup>1</sup> Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

<sup>2</sup> Fertility and Infertility Research Center, Research Institute for Health Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran



## Highlights

- There was no difference among the female age, duration and cause of infertility, number of ART cycles and AMH levels in patients with TFS and TEF and other patients.
- Serum levels of E2, number of COCs, MII oocytes and transferred embryos were higher in patients with TFS and TEF.
- High-quality embryo chemical and clinical pregnancy rates were similar in patients with TFS and TEF and other patients.
- The rates of good quality embryos, chemical and clinical pregnancy were higher in patients with TFS and TEF and >5 MII oocyte.

## Article Info

**Receive Date:** 12 January 2021

**Revise Date:** 17 March 2021


**Accept Date:** 05 April 2021

**Available online:** 12 April 2021

## Keywords:

ART treatments  
 Fertilization  
 Human embryo  
 Pregnancy

## Graphical Abstract



## Abstract

This retrospective study was aimed to investigate the characteristics of cycles with 100% achievement in laboratory procedures to determine the predictors of cycles with total fertilization success (TFS) and following total embryo formation (TEF). 273 ART cycles were categorized into two groups of the case (n= 121) and control (n=152). Inclusion criteria for case group were; cycles that a total number of MII oocytes were fertilized, and a total of fertilized oocytes developed into the embryos. Demographic variables, ART cycle characteristics and clinical outcomes were assessed and compared between groups. In subcategorizing, the case group was divided into two groups; A) patients with five or fewer ( $\leq 5$ ) MII oocytes (n=94); B) patients with more than five ( $> 5$ ) MII oocytes (n=27). Clinical outcomes were assessed between subgroups of A, B and control. Man-Whitney U test, independent sample test and chi-square test were applied wherever appropriate to compare between two groups. P-value less than 0.5 were considered significant. Serum levels of E2, number of COCs, MII oocytes and transferred embryos differed between the groups ( $P < 0.0001$  and  $P = 0.001$ ). There was a trend manner in increasing the rate of ICSI in case group rather than controls (76.9% vs. 67.1%, respectively;  $P = 0.081$ ). Furthermore, data sub-analysis showed that the rates of good quality embryos, chemical and clinical pregnancies were higher in subgroup B rather than the other subgroup; however, the differences were not significant ( $P = 0.07$ , 0.71 and 0.07, respectively). To increase the likelihood of a successful pregnancy in ART cycles, higher good quality embryos and appropriate number of available embryos for transfer could play an important role.

© 2021 Published by CAS-Press.



doi: 10.22034/CAJMPSCI.2021.02.06

E-ISSN: 2783-0993

\*Corresponding author: [khalili59@hotmail.com](mailto:khalili59@hotmail.com) (M.A. Khalili)

## Introduction

In vitro fertilization (IVF) has become a promising option that helped many infertile couples to realize their dream of having children. However, the most important concern in IVF programs is unsuccessful implantation after embryo transfer (1). It has been estimated that implantation failure occurs in 85% of the transferred embryos (2). In 2012 in Europe, assisted reproductive technology (ART) cycles including 139978 of IVF and 312,600 of the intracytoplasmic sperm injection (ICSI) resulted in 29.4 and 27.8% of clinical pregnancy rates per aspiration, respectively (3). Several clinical and non-clinical parameters predicting the implantation and pregnancy outcomes during IVF treatments including female age, duration of subfertility, type of subfertility, indication for IVF, basal FSH, number of oocytes retrieved, method of fertilization (IVF or ICSI), number of embryos transferred, uterine receptivity, gamete and embryo qualities and transfer efficiency (4, 5).

Moreover, in the case of apparently normal sperm quality, total fertilization failure (TFF) occurs in 5-15% of the couples undergoing the IVF treatment. TFF cycles may be explained by lack of penetration of the zona pellucida (ZP), an oocyte activation failure, or a defect in the oocyte integrity (6). However, ICSI can bypass those barriers and can be an effective way to overcome the TFF or low fertilization rates (6, 7). Although, generally accepted that the indication for ICSI is a severe male factor or previous fertilization failure following IVF (8), but it has been frequently performed alone or in combination with IVF in couples with other etiologies of infertility (9, 10). Reports regarding the benefits of ICSI in non-male factor cases have shown controversial results. Some studies have shown a higher fertilization rate and lower fertilization failure by using ICSI (11, 12). Whereas the other studies do not support the advantages of ICSI in the prevention of TFF (13), and its influences on the other clinical outcomes, such as the embryo quality, implantation and clinical pregnancy rates (14, 15). Regarding the possible factors influencing the success of ART cycles, this study assessed the characteristics of cycles with 100% achievement in laboratory procedures to determine which factors may be predictive of cycles with total fertilization success (TFS) and following total embryo formation (TEF).

## Materials and Methods

### Study design

In this retrospective study, laboratory and clinical data from patients undergoing ART programs from March 2016 to April 2017 were analyzed. Cycles with severe male factor (sperm concentration  $< 4 \times 10^6$ /ml), frozen and surgically retrieved spermatozoa, also donation and surrogacy cycles were excluded from the study. The eligibility criteria for selecting the case group were the patients with the same number of MII oocytes, fertilized oocytes and developed embryos. Demographic variables, ART cycle characteristics and clinical outcomes were assessed in the case group and compared with the controls. In subcategorizing, the case group was divided into two groups: A) the patients with five or fewer ( $\leq 5$ ) MII oocytes; B) the patients with more than five ( $> 5$ ) MII oocytes. The clinical outcomes were assessed between subgroups A, B and control. This study was approved by the author's institute ethics committee.

### Ovarian stimulation and IVF/ICSI procedure

Ovarian stimulation was achieved by long pituitary down-regulation using a combination of a gonadotrophin-releasing hormone (GnRH) agonist or antagonist and FSH (Gonal-F; Serono, Geneva, Switzerland). The recombinant hCG (rhCG; IBSA Co, Switzerland) was administered when the maximum diameter of leading follicles was exceeded 18 mm, followed 36 h later by oocyte retrieval. The retrieved cumulus-oocyte complexes (COCs) were incubated at 37 °C in 6% CO<sub>2</sub> and 95% air until undergoing IVF or ICSI. In cycles with a plan of ICSI, the COCs were denuded of their cells by 30-60 s exposure to HEPES buffered medium containing 80 IU/mL hyaluronidase (Irvine Sci, CA, USA) followed by pipetting the COCs with a pasture pipette. ICSI procedure was performed as described previously (16).

### Fertilization and embryo assessments

Oocytes were checked for signs of fertilization 18-20 h after insemination or 16-18 h after injection. Fertilization was approved by the presence of two pronuclei (2PN) and two polar bodies. 2 days of embryos were graded as follows: Grade A: equal size blastomeres without fragmentation, Grade B: slightly unequal blastomere, up to 10% cytoplasmic fragments. Grade C: unequal-sized blastomeres up to 50% fragments and large granules. Grade D: unequal blastomeres with significant fragmentation and large black granules (17). Grades A and B were regarded as high-quality embryos. In the all of the culture steps, the oocytes and embryos were incubated on the 5% O<sub>2</sub> and 6% CO<sub>2</sub>. Results of chemical pregnancy were determined 14 days after embryo transfer (ET) on day 2. Furthermore, the clinical pregnancy was defined as fetal heartbeat rate (FHR) confirmation by sonography.

### Statistical analysis

The data were presented as median (min-max) and mean  $\pm$  SD for quantitative and percentage for qualitative data. Man-Whitney U test, independent sample test and chi-square test were applied wherever appropriate to compare between two groups. All hypotheses were considered two-tailed and a significant level was defined at  $P \leq 0.05$ .

### Results

Table 1 summarized the demographic, laboratory and cycle characteristics of the patients with TFS and TEF (case group) and control group. There were no significant differences in female age, duration and cause of infertility, the number of ART cycles and also in levels of AMH between the groups. Although, the levels of serum E<sub>2</sub>, the number of COCs, MII oocytes and transferred embryos differed between the groups ( $P < 0.0001$  and  $P = 0.001$ , Table 1). However, the method of fertilization was not significantly differed between groups, but there was a trend in increasing the rate of ICSI in the case group rather than control (76.9% vs. 67.1%, respectively;  $P = 0.081$ ). The rates of high-quality embryos (A + B), chemical and clinical pregnancy showed no significant differences between the groups (Table 2). According to Table 3, data subanalysis showed that the rates of good quality embryos, chemical and clinical pregnancy were higher in subgroup B rather the other subgroup; however, the differences were not significant ( $P = 0.07, 0.71$ , and  $0.07$ , respectively).

**Table 1.** Comparison of demographic, laboratory and cycle characteristics between two study groups.

Variables	Case group	Control group	P-value
NO. of cycles	121	152	
Female age *	32.8 $\pm$ 4.75	31.1 $\pm$ 4.47	0.521
Duration of infertility	8 (1-25)	7 (1-24)	0.171
<b>Cause of infertility (%)</b>			
Male factor	38.8	43.4	
PCOs	7.4	15.1	
TF	9.9	5.9	0.066
OF	16.5	8.6	
Endometriosis	4.1	2.6	
Male and female factor	16.2	14.5	
Unexplained	7	9.9	
Serum E <sub>2</sub>	1100 (121-6021)	1385 (147-9891)	<0.0001
AMH	2.4 (0.2-20)	2.75 (0.6-11.6)	0.148
NO. of ART cycle	1.18 $\pm$ 0.8	1.47 $\pm$ 0.7	0.402
NO. of COCs	4 (1-14)	8 (2-44)	<0.0001

**Table 1. Continue.**

NO. of MII oocytes	2 (1-13)	7 (2-39)	<0.0001
NO. of immature oocytes	0 (0-6)	1 (0-14)	0.331
<b>Method of fertilization (%)</b>			
IVF	23.1	32.9	0.081
ICSI	76.9	67.1	
NO. of transferred embryo *	1.72± 0.46	1.92± 0.48	0.001

Data are presented as median (min-max) except \* presented as mean± SD. PCOs: polycystic ovarian syndrome, TF: tubal factor, OF: ovarian factor, E2: estradiol, AMH: anti-mullerian hormone, ART: assisted reproductive technology, COCs: cumulus-oocyte complex, MII: metaphase II, IVF: in vitro fertilization, ICSI: intracytoplasmic sperm injection.

**Table 2.** Clinical outcomes of ART cycles in case and control groups.

Variables	Case group	Control group	P-value
Fertilization rate *	100	63.9± 21.6	<0.0001
Embryo formation rate *	100	88.8± 19.2	<0.0001
Good quality embryos rate (%)	86.8 (105.121)	85.5 (130.152)	0.987
Chemical pregnancy rate (%)	32.2 (39.121)	35.5 (54.152)	0.608
Clinical pregnancy rate (%)	18.2 (22.121)	20.4 (31.152)	0.758

\* Data are presented as mean± SD.

**Table 3.** Clinical outcomes of ART cycles in subgroup A ( $\leq 5$  MII oocyte), subgroup B ( $> 5$  MII oocyte) and control group.

Variables (%)	Subgroup A ( $\leq 5$ MII oocyte)	Subgroup B ( $> 5$ MII oocyte)	Control group	P-value
Good quality embryos	83 (78/94)	100 (27/27)	85.5 (130/152)	0.07
Chemical	30.9 (29/94)	37(10/27)	35.5 (54/152)	0.71
Clinical pregnancy	13.8 (13/94)	33.3(9/27)	20.4 (31/152)	0.07

## Discussion

This retrospective cohort study on 273 IVF/ICSI treatments is the first study on the TFS and following TEF cycles for finding the probable predictive factors and enhancing the chance of success in clinical outcomes. However, data do not show any significant differences in the pregnancy rates of these cycles compared to control (Table 2). The female age was considered as one of the strongest factors in predicting pregnancy chances after IVF treatments (4, 18). Moreover, the oocyte morphological quality could be related to advanced maternal age (19). However, this study group was not significantly differed in the female age from the control group. In one study, the embryo quality was introduced as the better predictor of pregnancy rather than the number of transferred embryos and female age (20). Two other factors associated with pregnancy rates are the duration and cause of infertility (21). In the present study, these two late factors were matched between case and control groups, so they cannot be the predictive factors for TFS and TEF in ART programs.

AMH is a member of the transforming growth factor- $\beta$  superfamily produced exclusively by granulosa cells, which declines with age, and is widely considered as a sensitive marker of ovarian reserve (22, 23). The predictive ability of AMH for pregnancy outcomes is age-dependent (24), so AMH linearly reflects oocyte quantity and quality, both declining related to the advancing female age (25). The presented data confirmed no significant differences in the AMH levels between the groups (Table 1). Based on the above-mentioned studies regarding that the AMH is age-dependent, such results will be expected from the analysis due to the similar mean of female age in both groups. Furthermore, the results of the studies are inconsistent in the association of

AMH with implantation, pregnancy and live birth rate in assisted reproduction [26, 27]. A recent meta-analysis of 5,373 women examining the association of AMH with implantation and clinical pregnancy showed that its predictive accuracy for these parameters is poor (28).

As shown in Table 1, the serum E<sub>2</sub> levels and the number of retrieved COCs and MII oocytes were significantly lower in the case group compared to the control group. Serum E<sub>2</sub> plays an important role in follicular and oocyte maturation, and also in uterus preparation for embryo implantation (29). Moreover, it was mentioned that usually, serum E<sub>2</sub> levels in hCG administration day could predict the approximate number of COCs in that cycle (30). There was a debate on the impact of elevated E<sub>2</sub> levels on the quality and outcomes of the cycles. Some studies showed that supraphysiological E<sub>2</sub> levels do not adversely affect the quality of developing oocytes and embryos (31). Whereas, numerous studies have shown lower pregnancy and implantation rates in relation to elevated levels of E<sub>2</sub> caused by disrupted endometrial receptivity (32). In the group with lower levels of E<sub>2</sub>, the results showed significantly higher fertilization and embryo formation rates without a concomitant rise in chemical and clinical pregnancy outcomes.

There are some studies on the association between the number of oocytes retrieved and pregnancy (21, 33). The availability of an optimum number of MII oocytes improves the likelihood of generating good quality embryos and consequently achieving successful outcomes (34). Sharma and colleagues reported a higher cumulative conception rate in patients with more than five retrieved oocytes (35). In the case group of this study, there were higher rates of fertilization and embryo formation despite the fewer number of retrieved COCs and MII oocytes retrieved. However, the chemical and clinical pregnancy was insignificantly lower when compared to the control group. In a subanalysis, the group with TFS and TEF was divided into two subgroups regarding the number of retrieved oocytes. Data showed a significantly higher clinical pregnancy rate in TFS and TEF patients with more than five oocytes in comparison to the other groups (33.3% vs. 13.8%, and 20.4%, P= 0.07). Moreover, the number of embryos transferred was influenced on IVF success, as the patients with more than two embryos available for transfer had significantly higher pregnancy chances (35). The number of embryos transferred in the case group was significantly lower and subsequently, chemical and clinical pregnancy showed a lower rate. In the TFS and TEF group, the number of cases with only one embryo available for transfer was higher compared to the control group due to the higher number of cycles with only one retrieved oocyte. So, according to the lower number of available embryos for transfer in each cycle, the lower clinical pregnancy rate is reliable and predictable. For resolving this problem, the chemical and clinical pregnancy rates were separately analyzed in subgroups in order to the number of MII oocytes. In regards to the relationship of the method of fertilization with a chance of pregnancy, some studies reported a lower pregnancy rate in ICSI rather than IVF programs (30), although the other studies showed insignificant differences (36). Also, the results showed no significant differences in performed fertilization method.

## Conclusion

In conclusion, the data do not show any specific parameter that could be influenced by TFS and TEF. However, according to our findings, the cycles with the higher-good quality embryos and the appropriate number of available embryos for transfer will have a better prognosis for the pregnancy success.

## References

1. Vaegter KK, Lakic TG, Olovsson M, Berglund L, Brodin T, Holte J. Which factors are most predictive for live birth after in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) treatments? Analysis of 100 prospectively recorded variables in 8,400 IVF/ICSI single-embryo transfers. *Fertil Steril* 2017; 107(3): 641-648. <https://doi.org/10.1016/j.fertnstert.2016.12.005>
2. Edwards R. Clinical approaches to increasing uterine receptivity during human implantation. *Hum Reprod* 1995; 10: 60-66. [https://doi.org/10.1093/humrep/10.suppl\\_2.60](https://doi.org/10.1093/humrep/10.suppl_2.60)
3. Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, Erb K, Mocanu E, Motrenko T, Scaravelli G, Wyns C, Goossens V. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. *Hum Reprod* 2016; 31(8): 1638-1652. <https://doi.org/10.1093/humrep/dew151>

4. Van Loendersloot L, Van Wely M, Limpens J, Bossuyt P, Repping S, Van Der Veen F. **Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis.** Hum Reprod Update 2010; 16(6): 577-589. <https://doi.org/10.1093/humupd/dmq015>
5. Cetin MT, Kumtepe Y, Kiran H, Seydaoglu Ga. **Factors affecting pregnancy in IVF: age and duration of embryo transfer.** Reprod Biomed Online 2010; 20(3): 380-386. <https://doi.org/10.1016/j.rbmo.2009.12.008>
6. van der Westerlaken L, Helmerhorst F, Dieben S, Naaktgeboren N. **Intracytoplasmic sperm injection as a treatment for unexplained total fertilization failure or low fertilization after conventional in vitro fertilization.** Fertil Steril 2005; 83(3): 612-617. <https://doi.org/10.1016/j.fertnstert.2004.08.029>
7. Kastrop P, Weima S, Van Kooij R, Te Velde E. **Comparison between intracytoplasmic sperm injection and in vitro fertilization (IVF) with high insemination concentration after total fertilization failure in a previous IVF attempt.** Hum Reprod 1999; 14(1): 65-69. <https://doi.org/10.1093/humrep/14.1.65>
8. Krog M, Prior M, Carlsen E, Loft A, Forman J, Pinborg A, Andersen AN. **Fertilization failure after IVF in 304 couples—a case-control study on predictors and long-term prognosis.** Eur J Obstet Gynecol Reprod Biol 2015; 184: 32-37. <https://doi.org/10.1016/j.ejogrb.2014.10.037>
9. Ferraretti AP, Goossens V, De Mouzon J, Bhattacharya S, Castilla JA, Korsak V, Kupka M, Nygren KG, Nyboe Andersen A. **Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE.** Hum Reprod 2012; 27(9): 2571-2584. <https://doi.org/10.1093/humrep/des255>
10. Nyboe Andersen A, Carlsen E, Loft A. **Trends in the use of intracytoplasmic sperm injection marked variability between countries.** Hum Reprod Update 2008; 14: 593-604. <https://doi.org/10.1093/humupd/dmn032>
11. Bungum L, Bungum M, Humaidan P, Andersen CY. **A strategy for treatment of couples with unexplained infertility who failed to conceive after intrauterine insemination.** Reprod Biomed online 2004; 8(5): 584-589. [https://doi.org/10.1016/S1472-6483\(10\)61107-8](https://doi.org/10.1016/S1472-6483(10)61107-8)
12. Hershlag A, Paine T, Kvapil G, Feng H, Napolitano B. **In vitro fertilization-intracytoplasmic sperm injection split: an insemination method to prevent fertilization failure.** Fertil Steril 2002; 77(2): 229-232. [https://doi.org/10.1016/S0015-0282\(01\)02978-8](https://doi.org/10.1016/S0015-0282(01)02978-8)
13. Kim JY, Kim JH, Jee BC, Lee JR, Suh CS, Kim SH. **Can intracytoplasmic sperm injection prevent total fertilization failure and enhance embryo quality in patients with non-male factor infertility?** Eur J Obstet Gynecol Reprod Biol 2014; 178: 188-191. <https://doi.org/10.1016/j.ejogrb.2014.03.044>
14. Foong SC, Fleetham JA, O'Keane JA, Scott SG, Tough SC, Greene CA. **A prospective randomized trial of conventional in vitro fertilization versus intracytoplasmic sperm injection in unexplained infertility.** J Assist Reprod Genet 2006; 23(3): 137-140. <https://doi.org/10.1007/s10815-005-9008-y>
15. Kim HH, Bundorf MK, Behr B, McCallum SW. **Use and outcomes of intracytoplasmic sperm injection for non-male factor infertility.** Fertil Steril 2007; 88(3): 622-628. <https://doi.org/10.1016/j.fertnstert.2006.12.013>
16. Ashourzadeh S, Khalili MA, Omid M, Mahani SN, Kalantar SM, Aflatoonian A, Habibzadeh V. **Noninvasive assays of in vitro matured human oocytes showed insignificant correlation with fertilization and embryo development.** Arch Gynecol Obstet 2015; 292(2): 459-463. <https://doi.org/10.1007/s00404-015-3644-y>
17. Hill GA, Freeman M, Bastias MC, Rogers BJ, Herbert III CM, Osteen KG, Wentz AC. **The influence of oocyte maturity and embryo quality on pregnancy rate in a program for in vitro fertilization-embryo transfer.** Fertil Steril 1989; 52(5): 801-806. [https://doi.org/10.1016/S0015-0282\(16\)61034-8](https://doi.org/10.1016/S0015-0282(16)61034-8)
18. Sabatini L, Zosmer A, Hennessy E, Tozer A, Al-Shawaf T. **Relevance of basal serum FSH to IVF outcome varies with patient age.** Reprod Biomed online 2008; 17(1): 10-19. [https://doi.org/10.1016/S1472-6483\(10\)60287-8](https://doi.org/10.1016/S1472-6483(10)60287-8)
19. Omid M, Khalili MA, Nahangi H, Ashourzadeh S, Rahimipour M. **Does women's age influence zona pellucida birefringence of metaphase II oocytes in in-vitro maturation program?** Iran J Reprod Med 2013; 11(10): 823.
20. Terriou P, Sapin C, Giorgetti C, Hans E, Spach JL, Roulier R. **Embryo score is a better predictor of pregnancy than the number of transferred embryos or female age.** Fertil Steril 2001; 75(3): 525-531. [https://doi.org/10.1016/S0015-0282\(00\)01741-6](https://doi.org/10.1016/S0015-0282(00)01741-6)
21. Ottosen LD, Kesmodel U, Hindkjær J, Ingerslev HJ. **Pregnancy prediction models and eSET criteria for IVF patients—do we need more information?** J Assist Reprod Genet 2007; 24(1): 29-36. <https://doi.org/10.1007/s10815-006-9082-9>

22. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. [Anti-Müllerian hormone \(AMH\) as a predictive marker in assisted reproductive technology \(ART\)](#). Hum Reprod Update 2009; 16(2): 113-130. <https://doi.org/10.1093/humupd/dmp036>
23. Gleicher N, Kushnir VA, Sen A, Darmon SK, Weghofer A, Wu YG, Wang Q, Zhang L, Albertini DF, Barad DH. [Definition by FSH, AMH and embryo numbers of good-, intermediate-and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH](#). J Transl Med 2016; 14(1): 172-182. <https://doi.org/10.1186/s12967-016-0924-7>
24. Tal R, Seifer DB, Khanimov M, Schwartz E, Grazi RV, Malter HE. [Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles](#). Reprod Biomed Online 2013; 26(4): 360-367. <https://doi.org/10.1016/j.rbmo.2012.12.002>
25. Nelson SM, Fleming R, Gaudoin M, Choi B, Santo-Domingo K, Yao M. [Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth](#). Fertil Steril 2015; 104(2): 325-332. <https://doi.org/10.1016/j.fertnstert.2015.04.032>
26. Nelson SM, Yates RW, Fleming R. [Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy](#). Hum Reprod 2007; 22(9): 2414-2421. <https://doi.org/10.1093/humrep/dem204>
27. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. [Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection](#). Fertil Steril 2007; 87(1): 223-226. <https://doi.org/10.1016/j.fertnstert.2006.06.019>
28. Tal R, Tal O, Seifer BJ, Seifer DB. [Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis](#). Fertil Steril 2015; 103(1): 119-130. <https://doi.org/10.1016/j.fertnstert.2014.09.041>
29. Anifandis G, Koutselini E, Louridas K, Liakopoulos V, Leivaditis K, Mantzavinos T, Sioutopoulou D, Vamvakopoulos N. [Estradiol and leptin as conditional prognostic IVF markers](#). Reproduction 2005; 129(4): 531-534. <https://doi.org/10.1530/rep.1.00567>
30. Var T, Tonguc E, Dogan M, Mollamahmutoglu L. [Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist](#). Gynecol Endocrinol 2011; 27(8): 558-561. <https://doi.org/10.3109/09513590.2010.501887>
31. Peña JE, Chang PL, Chan L-K, Zeitoun K, Thornton MH, Sauer MV. [Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles](#). Hum Reprod 2002; 17(1): 83-87. <https://doi.org/10.1093/humrep/17.1.83>
32. Kosmas IP, Kolibianakis EM, Devroey P. [Association of estradiol levels on the day of hCG administration and pregnancy achievement in IVF: a systematic review](#). Hum Reprod 2004; 19(11): 2446-2453. <https://doi.org/10.1093/humrep/deh473>
33. Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. [The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China](#). Hum Reprod 2013; 28(10): 2728-2734. <https://doi.org/10.1093/humrep/det303>
34. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. [The science behind 25 years of ovarian stimulation for in vitro fertilization](#). Endocr Rev 2006; 27(2): 170-207. <https://doi.org/10.1210/er.2005-0015>
35. Sharma V, Allgar V, Rajkhowa M. [Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility](#). Fertil Steril 2002; 78(1): 40-46. [https://doi.org/10.1016/S0015-0282\(02\)03160-6](https://doi.org/10.1016/S0015-0282(02)03160-6)
36. Strandell A, Bergh C, Lundin K. [Selection of patients suitable for one-embryo transfer may reduce the rate of multiple births by half without impairment of overall birth rates](#). Hum Reprod 2000; 15(12): 2520-2525. <https://doi.org/10.1093/humrep/15.12.2520>



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**How to cite this paper:**

Omidi M, Faramarzi A, Agha-Rahimi A, Farshchi FS, Khalili MA. [Total fertilization success and embryo formation in ART treatments; does it have any predictive value?](#) Cent Asian J Med Pharm Sci Innov 2021; 1(2): 97-103.